Key result
Prior therapy with atorvastatin or rosuvastatin in patients with acute myocardial infarction was associated with significantly lower serum acylation-stimulating protein levels (48.43 and 49.33 nmol/l, respectively) compared to non-statin users (57.25 nmol/l, P=0.0124).
Why the study?
Does prior and current statin therapy reduce acylation-stimulating protein (ASP) levels in patients presenting with acute myocardial infarction?
Population
111 patients with acute myocardial infarction admitted to a Coronary Care Unit, mean age 64.45, 71.17% male…
Comparison
Atorvastatin 20 mg/day or rosuvastatin 20 mg/day… vs Patients presenting with acute MI not previously…
Design
Cohort, Stated as 'randomized into three groups'
Authors
Loading...
Statin use was associated with lower ASP in AMI; hypothesis-generating and requires prospective validation before clinical consideration.
Cross-Sectional (n=111)
No
Does prior and current statin therapy reduce acylation-stimulating protein (ASP) levels in patients presenting with acute myocardial infarction?
Absolute Event Rate: 48.43% vs 57.25%
p-value: p=0.0124
Prior and current statin therapy is associated with significantly lower levels of the surrogate biomarker acylation-stimulating protein (ASP) in patients presenting with acute myocardial infarction.
Al‐kuraishy et al. (2017) conducted a cross-sectional in Acute myocardial infarction (n=111). Statins (Atorvastatin or Rosuvastatin) vs. Non-statin users was evaluated on Serum acylation-stimulating protein (ASP) levels (nmol/l) (p=0.0124). Prior therapy with atorvastatin or rosuvastatin in patients with acute myocardial infarction was associated with significantly lower serum acylation-stimulating protein levels (48.43 and 49.33 nmol/l, respectively) compared to non-statin users (57.25 nmol/l, P=0.0124).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: